These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 31280139

  • 21. Phillygenin regulates proliferation and apoptosis of non-small cell lung cancer through by AMPK/ERK/NF-κB axis.
    Wu S, Zhang Y, Zhang Y, Chen L, Xu X, Dang Y, Ti X.
    Pharmazie; 2020 Oct 01; 75(10):512-515. PubMed ID: 33305728
    [Abstract] [Full Text] [Related]

  • 22. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F.
    Clin Cancer Res; 2013 Jul 01; 19(13):3508-19. PubMed ID: 23695170
    [Abstract] [Full Text] [Related]

  • 23. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
    Shin DH, Choi YJ, Park JW.
    Cancer Res; 2014 Jan 01; 74(1):298-308. PubMed ID: 24240701
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A, Dennis PA.
    Cancer Res; 2008 Jan 15; 68(2):580-8. PubMed ID: 18199555
    [Abstract] [Full Text] [Related]

  • 26. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS, Oh B, Lee MH, Nam KY, Jin HR, Yang H, Choi J, Kim SW, Lee DH.
    Cancer Lett; 2016 Mar 01; 372(1):75-81. PubMed ID: 26723875
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.
    Suwei D, Liang Z, Zhimin L, Ruilei L, Yingying Z, Zhen L, Chunlei G, Zhangchao L, Yuanbo X, Jinyan Y, Gaofeng L, Xin S.
    J Hematol Oncol; 2015 Oct 26; 8():120. PubMed ID: 26503334
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
    Ye YT, Zhong W, Sun P, Wang D, Wang C, Hu LM, Qian JQ.
    J Ethnopharmacol; 2017 Mar 22; 200():107-116. PubMed ID: 28088493
    [Abstract] [Full Text] [Related]

  • 31. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
    Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.
    PLoS One; 2010 Nov 29; 5(11):e14124. PubMed ID: 21124782
    [Abstract] [Full Text] [Related]

  • 32. Ginsenoside metabolite compound K induces apoptosis and autophagy in non-small cell lung cancer cells via AMPK-mTOR and JNK pathways.
    Li C, Dong Y, Wang L, Xu G, Yang Q, Tang X, Qiao Y, Cong Z.
    Biochem Cell Biol; 2019 Aug 29; 97(4):406-414. PubMed ID: 30475650
    [Abstract] [Full Text] [Related]

  • 33. AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth.
    Xia YC, Zha JH, Sang YH, Yin H, Xu GQ, Zhen J, Zhang Y, Yu BT.
    Cell Death Dis; 2021 Apr 06; 12(4):365. PubMed ID: 33824293
    [Abstract] [Full Text] [Related]

  • 34. In Vitro and In Vivo Antitumor Effects of Pyrimethamine on Non-small Cell Lung Cancers.
    Lin MX, Lin SH, Lin CC, Yang CC, Yuan SY.
    Anticancer Res; 2018 Jun 06; 38(6):3435-3445. PubMed ID: 29848694
    [Abstract] [Full Text] [Related]

  • 35. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
    Wang Y, Xu W, Yan Z, Zhao W, Mi J, Li J, Yan H.
    J Exp Clin Cancer Res; 2018 Mar 20; 37(1):63. PubMed ID: 29554968
    [Abstract] [Full Text] [Related]

  • 36. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
    Meng J, Majidi M, Fang B, Ji L, Bekele BN, Minna JD, Roth JA.
    PLoS One; 2013 Mar 20; 8(10):e77067. PubMed ID: 24146957
    [Abstract] [Full Text] [Related]

  • 37. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK.
    J Natl Cancer Inst; 2004 Oct 20; 96(20):1536-48. PubMed ID: 15494604
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
    Jang SK, Hong SE, Lee DH, Kim JY, Kim JY, Hong J, Park IC, Jin HO.
    Anticancer Res; 2021 Jul 20; 41(7):3481-3487. PubMed ID: 34230143
    [Abstract] [Full Text] [Related]

  • 39. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
    Tsai AC, Pai HC, Wang CY, Liou JP, Teng CM, Wang JC, Pan SL.
    Br J Pharmacol; 2014 Jan 20; 171(1):122-33. PubMed ID: 24116948
    [Abstract] [Full Text] [Related]

  • 40. Ad-apoptin inhibits glycolysis, migration and invasion in lung cancer cells targeting AMPK/mTOR signaling pathway.
    Song G, Fang J, Shang C, Li Y, Zhu Y, Xiu Z, Sun L, Jin N, Li X.
    Exp Cell Res; 2021 Dec 15; 409(2):112926. PubMed ID: 34793774
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.